Page last updated: 2024-11-03

quetiapine and Weight Gain

quetiapine has been researched along with Weight Gain in 3 studies

Weight Gain: Increase in BODY WEIGHT over existing weight.

Research Excerpts

ExcerptRelevanceReference

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kroeze, WK1
Hufeisen, SJ1
Popadak, BA1
Renock, SM1
Steinberg, S1
Ernsberger, P1
Jayathilake, K1
Meltzer, HY1
Roth, BL1
Kim, SF1
Huang, AS1
Snowman, AM1
Teuscher, C1
Snyder, SH1
Lange, JH1
Reinders, JH1
Tolboom, JT1
Glennon, JC1
Coolen, HK1
Kruse, CG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332]Phase 420 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline Montgomery Asberg Depression Rating Scale

Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks

Interventionunits on a scale (Mean)
Arm 1-15.5
Arm 2-15.5

Weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8

Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks

,
Interventionkilograms (Mean)
BaselineWeek 1Week 4Week 6Week 8
Arm 1- ODT76.077.477.878.979.1
Arm 2- SOT76.177.678.379.480.1

Other Studies

3 other studies available for quetiapine and Weight Gain

ArticleYear
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:3

    Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Hum

2003
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Feb-27, Volume: 104, Issue:9

    Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemist

2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
    Journal of medicinal chemistry, 2007, Oct-18, Volume: 50, Issue:21

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac

2007